Spring 2027 Co-Op, General Ledger Accounting
Vertex Pharmaceuticals
Summary
The Vertex General Ledger Accounting Co-Op program is a 6-month experiential training program for students currently working towards an undergraduate or advanced degree in accounting or a related field. The selected intern will join the Global General Ledger ('GL') Accounting team, which operates under Vertex's Record to Report umbrella, managing and maintaining the company's global financial records to ensure accuracy, consistency, and compliance for financial reporting.
Job description
Your Impact
The Vertex General Ledger Accounting Co-Op program is a 6-month experiential training program for students currently working towards an undergraduate or advanced degree in accounting or a related field. The selected intern will join the Global General Ledger ('GL') Accounting team, which operates under Vertex's Record to Report umbrella, managing and maintaining the company's global financial records to ensure accuracy, consistency, and compliance for financial reporting.
Key Responsibilities
- GL Close Support - Gain hands-on experience with the monthly GL close by supporting cash management and other general accounting activities.
- Assist with post-close governance analysis to build an understanding of key close activities, dependencies, and opportunities to improve overall close efficiency.
- Project Assistance and Coordination - Provide support to the GL team on various projects and initiatives, which may include project testing, system implementations, integration activities, and process improvement efforts.
- Support may involve project coordination, action item tracking, documentation, testing, and other activities based on project needs.
What You Will Need to Succeed
- Currently enrolled in a college or university with at least two years completed toward a Bachelor's degree.
- Recent graduates are eligible if they are planning to return to graduate school.
- Minimum cumulative GPA of 3.2.
- Strong attention to detail and excellent organizational skills.
- Exceptional written and verbal communication abilities.
- Proven ability to manage multiple tasks in a fast-paced environment and prioritize effectively.
- Capable of working both independently and collaboratively within a team.
- Proficiency in Microsoft Office Suite (Excel, Word, PowerPoint, etc.).
- Previous internship or co-op experience in Accounting.
- Legal authorization to work in the United States, now and in the future.
- You must be enrolled in an advanced degree program if graduating before June 2027.
- You must be available to work full-time, 40 hours per week from January – June 2027.
Program Details
- Full-time, paid co-op $20.00-35.00 USD/hour
- Program Dates: January – June 2027
- Application Deadline: November 15th, 2026
Requirements
- Currently enrolled in a college or university with at least two years completed toward a Bachelor's degree
- Recent graduates eligible if planning to return to graduate school
- Minimum cumulative GPA of 3.2
- Strong attention to detail and excellent organizational skills
- Exceptional written and verbal communication abilities
- Proven ability to manage multiple tasks in a fast-paced environment and prioritize effectively
- Capable of working both independently and collaboratively within a team
- Proficiency in Microsoft Office Suite (Excel, Word, PowerPoint, etc.)
- Previous internship or co-op experience in Accounting
- Legal authorization to work in the United States, now and in the future
- Must be enrolled in an advanced degree program if graduating before June 2027
- Available to work full-time, 40 hours per week from January – June 2027
Benefits
- Gym access
- Group exercise classes
- Subsidized commuter benefits
- Free breakfast
- Career development opportunities
- Social events
- Medical, Dental & Vision
- Paid time off
- Educational assistance
- Student loan repayment
- Commuting subsidy
- Matching charitable donations
- 401(k)
Company overview
Vertex Pharmaceuticals is a global biotechnology company headquartered in Boston, Massachusetts, founded in 1989. The company specializes in discovering, developing, and commercializing transformative medicines for serious diseases, with a primary focus on cystic fibrosis (CF). Vertex has pioneered breakthrough therapies including TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which collectively treat approximately 90% of CF patients. Beyond CF, the company has expanded its portfolio to include treatments for sickle cell disease, transfusion-dependent beta thalassemia, acute pain, and has robust clinical pipelines in APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1, and alpha-1 antitrypsin deficiency. Vertex employs approximately 6,100 people globally and maintains research facilities in San Diego, California, and Milton Park, Oxfordshire, England. The company is publicly traded on NASDAQ (VRTX) and is recognized as one of the industry's top workplaces, consistently earning accolades for its innovative culture and patient-focused approach to drug development.